Psoriatic Arthritis – Unmet Need – Detailed, Expanded Analysis (US/EU)

TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, but competing biologics such as IL-17 inhibitors (Cosentyx, Taltz), IL-12/23 inhibitors (Stelara), IL-23 inhibitors (Tremfya, Skyrizi), and targeted oral therapies (Otezla, Xeljanz, Rinvoq) are increasingly challenging the dominance of TNF-alpha inhibitors in treating PsA. Recognizing gaps in PsA treatment and focusing on product differentiation may play a crucial role in an agent’s success in this competitive PsA space. This report outlines key unmet needs and offers tools for strategic decision-making in the PsA therapy market.


  • How do current therapies perform on key treatment drivers and goals for PsA?
  • Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities in PsA?
  • What are the prevailing areas of unmet need and opportunity in the PsA market?
  • What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new PsA drug?


Provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European rheumatologists and dermatologists fielded in February 2024

Key companies: AbbVie, Amgen, Pfizer, Johnson & Johnson Innovative Medicine, Novartis, Eli Lilly

Key drugs: Humira, Cosentyx, Taltz, Stelara, Tremfya, Otezla, Rinvoq

launch Related Market Assessment Reports